Suppr超能文献

随机对照试验中竞争风险的考量:综述与改进建议

Accounting for competing risks in randomized controlled trials: a review and recommendations for improvement.

作者信息

Austin Peter C, Fine Jason P

机构信息

Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.

Institute of Health Management, Policy and Evaluation, University of Toronto, Toronto, Ontario, Canada.

出版信息

Stat Med. 2017 Apr 15;36(8):1203-1209. doi: 10.1002/sim.7215. Epub 2017 Jan 19.

Abstract

In studies with survival or time-to-event outcomes, a competing risk is an event whose occurrence precludes the occurrence of the primary event of interest. Specialized statistical methods must be used to analyze survival data in the presence of competing risks. We conducted a review of randomized controlled trials with survival outcomes that were published in high-impact general medical journals. Of 40 studies that we identified, 31 (77.5%) were potentially susceptible to competing risks. However, in the majority of these studies, the potential presence of competing risks was not accounted for in the statistical analyses that were described. Of the 31 studies potentially susceptible to competing risks, 24 (77.4%) reported the results of a Kaplan-Meier survival analysis, while only five (16.1%) reported using cumulative incidence functions to estimate the incidence of the outcome over time in the presence of competing risks. The former approach will tend to result in an overestimate of the incidence of the outcome over time, while the latter approach will result in unbiased estimation of the incidence of the primary outcome over time. We provide recommendations on the analysis and reporting of randomized controlled trials with survival outcomes in the presence of competing risks. © 2017 The Authors. Statistics in Medicine published by John Wiley & Sons Ltd.

摘要

在以生存或事件发生时间为结局的研究中,竞争风险是指其发生会排除感兴趣的主要事件发生的一种事件。在存在竞争风险的情况下,必须使用专门的统计方法来分析生存数据。我们对发表在高影响力综合医学期刊上的具有生存结局的随机对照试验进行了综述。在我们确定的40项研究中,31项(77.5%)可能易受竞争风险影响。然而,在这些研究中的大多数,在所述的统计分析中并未考虑竞争风险的潜在存在。在31项可能易受竞争风险影响的研究中,24项(77.4%)报告了Kaplan-Meier生存分析的结果,而只有5项(16.1%)报告在存在竞争风险的情况下使用累积发病率函数来估计结局随时间的发生率。前一种方法往往会导致对结局随时间发生率的高估,而后一种方法将导致对主要结局随时间发生率的无偏估计。我们针对存在竞争风险时具有生存结局的随机对照试验的分析和报告提供了建议。© 2017作者。《医学统计学》由John Wiley & Sons Ltd出版。

相似文献

1
Accounting for competing risks in randomized controlled trials: a review and recommendations for improvement.
Stat Med. 2017 Apr 15;36(8):1203-1209. doi: 10.1002/sim.7215. Epub 2017 Jan 19.
3
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
4
Eliciting adverse effects data from participants in clinical trials.
Cochrane Database Syst Rev. 2018 Jan 16;1(1):MR000039. doi: 10.1002/14651858.MR000039.pub2.
5
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
6
Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery.
Cochrane Database Syst Rev. 2018 Jul 9;7(7):CD011492. doi: 10.1002/14651858.CD011492.pub2.
7
Non-contraceptive oestrogen-containing preparations for controlling symptoms of premenstrual syndrome.
Cochrane Database Syst Rev. 2017 Mar 3;3(3):CD010503. doi: 10.1002/14651858.CD010503.pub2.
8
Interventions for central serous chorioretinopathy: a network meta-analysis.
Cochrane Database Syst Rev. 2025 Jun 16;6(6):CD011841. doi: 10.1002/14651858.CD011841.pub3.
9
Interventions for implementation of thromboprophylaxis in hospitalized patients at risk for venous thromboembolism.
Cochrane Database Syst Rev. 2018 Apr 24;4(4):CD008201. doi: 10.1002/14651858.CD008201.pub3.
10
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.

引用本文的文献

2
Uncertainties in outcome modelling in radiation oncology.
Phys Imaging Radiat Oncol. 2025 May 7;34:100774. doi: 10.1016/j.phro.2025.100774. eCollection 2025 Apr.
5
Modeling of Disease Progression of Type 2 Diabetes Using Real-World Data: Quantifying Competing Risks of Morbidity and Mortality.
CPT Pharmacometrics Syst Pharmacol. 2025 Mar;14(3):606-615. doi: 10.1002/psp4.13301. Epub 2025 Jan 17.
6
Long-Term Effect of Intensive vs Standard Blood Pressure Control on Mild Cognitive Impairment and Probable Dementia in SPRINT.
Neurology. 2025 Feb 11;104(3):e213334. doi: 10.1212/WNL.0000000000213334. Epub 2025 Jan 16.

本文引用的文献

1
Developing points-based risk-scoring systems in the presence of competing risks.
Stat Med. 2016 Sep 30;35(22):4056-72. doi: 10.1002/sim.6994. Epub 2016 May 19.
2
Introduction to the Analysis of Survival Data in the Presence of Competing Risks.
Circulation. 2016 Feb 9;133(6):601-9. doi: 10.1161/CIRCULATIONAHA.115.017719.
3
Competing risk bias was common in Kaplan-Meier risk estimates published in prominent medical journals.
J Clin Epidemiol. 2016 Jan;69:170-3.e8. doi: 10.1016/j.jclinepi.2015.07.006. Epub 2015 Jul 29.
4
Competing risks analyses: objectives and approaches.
Eur Heart J. 2014 Nov 7;35(42):2936-41. doi: 10.1093/eurheartj/ehu131. Epub 2014 Apr 7.
5
Number needed to treat for time-to-event data with competing risks.
Stat Med. 2014 Jan 30;33(2):181-92. doi: 10.1002/sim.5922. Epub 2013 Sep 4.
6
A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions.
J Clin Epidemiol. 2013 Jun;66(6):648-53. doi: 10.1016/j.jclinepi.2012.09.017. Epub 2013 Feb 14.
7
Competing risks and the clinical community: irrelevance or ignorance?
Stat Med. 2012 May 20;31(11-12):1089-97. doi: 10.1002/sim.4384. Epub 2011 Sep 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验